For instance, the therapeutic targeting of FASN is currently being explored in a phase 2 clinical trial in patients with glioblastoma using the FASN inhibitor TVB-2640 in combination with bevacizumab (NCT03032484) (28). Here, FASN is linked to glioblastoma.